The targeted next generation sequencing of thyroid nodules revealed BRAFV600E as the most prevalent mutation in patients with thyroid cancer (45% of examined nodules) and either no mutation or mutation in the RAS gene (NRAS Q61R, HRAS Q61K) in benign thyroid lesions (Supplemental Table 1). The gene discussed is NRAS; the disease is thyroid nodule.